title: Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.
abstract: The erbB-2 oncogene encodes a transmembrane protein tyrosine kinase which plays a pivotal role in signal transduction and has been implicated when overexpressed in breast, ovarian, and gastric cancers. Naturally occurring benzoquinoid ansamycin antibiotics herbimycin A, geldanamycin (GDM), and dihydrogeldanamycin were found to potently deplete p185, the erbB-2 oncoprotein, in human breast cancer SKBR-3 cells in culture. Chemistry efforts to modify selectively the quinoid moiety of GDM afforded derivatives with greater potency in vitro and in vivo. Analogs demonstrated inhibition of p185 phosphotyrosine in cell culture and in vivo after systemic drug administration to nu/nu nude mice bearing Fisher rat embryo cells transfected with human erbB-2 (FRE/erbB-2). Specifically, dosed intraperitoneally at 100 mg/kg, 17-(allylamino)-17-demethoxygeldanamycin and other 17-amino analogs were effective at reducing p185 phosphotyrosine in subcutaneous flank FRE/erbB-2 tumors. Modifications to the 17-19-positions of the quinone ring revealed a broad structure-activity relationship in vitro.
authors.affiliation: Pfizer Central Research, Groton, Connecticut 06340, USA.
authors.forename: R C
authors.initials: RC
authors.lastname: Schnur
authors.forename: M L
authors.initials: ML
authors.lastname: Corman
authors.forename: R J
authors.initials: RJ
authors.lastname: Gallaschun
authors.forename: B A
authors.initials: BA
authors.lastname: Cooper
authors.forename: M F
authors.initials: MF
authors.lastname: Dee
authors.forename: J L
authors.initials: JL
authors.lastname: Doty
authors.forename: M L
authors.initials: ML
authors.lastname: Muzzi
authors.forename: J D
authors.initials: JD
authors.lastname: Moyer
authors.forename: C I
authors.initials: CI
authors.lastname: DiOrio
authors.forename: E G
authors.initials: EG
authors.lastname: Barbacci
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology; D000903:Antibiotics, Antineoplastic / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D016227:Benzoquinones; D001943:Breast Neoplasms / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D047029:Lactams, Macrocyclic; D051379:Mice; D008819:Mice, Nude; D019000:Phosphotyrosine / Q000378:metabolism; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011809:Quinones / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D017828:Rifabutin / Q000031:analogs & derivatives; D013329:Structure-Activity Relationship; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D016227:Benzoquinones; D047029:Lactams, Macrocyclic; D019000:Phosphotyrosine; D011505:Protein-Tyrosine Kinases; D011809:Quinones; D018719:Erb-b2 Receptor Tyrosine Kinases; D017828:Rifabutin; C020754:herbimycin; C001277:geldanamycin